Genzyme and ICGEB form collaboration
The collaboration between Genzyme and the International Center for Genetic Engineering and Biotechnology (ICGEB) will initially focus on the development of new, improved treatments for malaria. ICGEB and
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.